PTJ
TSHA icon

Paul Tudor Jones’s Taysha Gene Therapies TSHA Stock Holding History

Paul Tudor Jones’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-143,575
Closed -$642K – 4289
2026
Q1 		$642K Buy
+143,575
New +$668K ﹤0.01% 2656
2024
Q3 		– Sell
-26,634
Closed -$59.7K – 3116
2024
Q2 		$59.7K Buy
+26,634
New +$77.5K ﹤0.01% 2224
2020
Q4 		– Sell
-9,725
Closed -$218K – 1637
2020
Q3 		$218K Buy
+9,725
New +$229K 0.01% 1118

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paul Tudor Jones's TSHA Position: Q2 2026 in Review

Paul Tudor Jones sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 143,575 shares — an estimated $642K sold.

Paul Tudor Jones first reported a position in TSHA in Q3 2020 and held it in 3 quarters. The position peaked at $642K in Q1 2026. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Paul Tudor Jones reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 143,575 Taysha Gene Therapies shares in Q2 2026, an estimated $642K.
  • Paul Tudor Jones first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 3 quarters.
  • Paul Tudor Jones's Taysha Gene Therapies position peaked at $642K in Q1 2026.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.